Drug
Asp2138
Asp2138: highest development phase Phase 3, developed by Astellas. 1 trial record tracked on RxWires.
- Highest phase
- Phase 3
- Developer
- Astellas
Trials
| Drug | Phase | Indication |
|---|---|---|
| ASP2138 NCT07673887 | Phase 3 | Gastric Adenocarcinoma |
Latest
No recent events.
Follow Asp2138 on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.
Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.